Bavarian Nordic News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.12.24	Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India (GlobeNewswire)
13.12.24	Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such (GlobeNewswire)
13.12.24	New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic (GlobeNewswire)
29.11.24	Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such (GlobeNewswire)
29.11.24	Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise (GlobeNewswire)
15.11.24	Bavarian Nordic Announces Interim Results for the First Nine Months of 2024 (GlobeNewswire)
29.10.24	First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine (GlobeNewswire)
26.09.24	Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines (GlobeNewswire)
26.09.24	Bavarian Nordic Upgrades its Financial Guidance for 2024 (GlobeNewswire)
24.09.24	Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines (GlobeNewswire)
19.09.24	Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents (GlobeNewswire)
18.09.24	Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa (GlobeNewswire)
13.09.24	Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine (GlobeNewswire)
12.09.24	Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation (GlobeNewswire)
06.09.24	Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such (GlobeNewswire)
05.09.24	Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such (GlobeNewswire)
05.09.24	First Doses of Bavarian Nordic’s Mpox Vaccine Now Arriving in the Democratic Republic of Congo (GlobeNewswire)
05.09.24	Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise (GlobeNewswire)
27.08.24	Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore (GlobeNewswire)
23.08.24	Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such (GlobeNewswire)
22.08.24	Bavarian Nordic Announces First Half 2024 Results (GlobeNewswire)
21.08.24	Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country (GlobeNewswire)
17.08.24	Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders (GlobeNewswire)
16.08.24	Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents (GlobeNewswire)
13.08.24	Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in Africa (GlobeNewswire)
13.08.24	Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine (GlobeNewswire)
08.08.24	Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine Production (GlobeNewswire)
26.07.24	Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine (GlobeNewswire)
18.07.24	Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine (GlobeNewswire)
01.07.24	Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked Loan (GlobeNewswire)
28.06.24	Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa (GlobeNewswire)
26.06.24	Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA (GlobeNewswire)
17.06.24	Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate (GlobeNewswire)
31.05.24	Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine (GlobeNewswire)
30.05.24	Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa (GlobeNewswire)
22.05.24	Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise (GlobeNewswire)
21.05.24	Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program (GlobeNewswire)
21.05.24	EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic (GlobeNewswire)
08.05.24	Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations (GlobeNewswire)
08.05.24	Bavarian Nordic Announces Interim Results for the First Three Months of 2024 (GlobeNewswire)
07.05.24	Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such (GlobeNewswire)
29.04.24	Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve (GlobeNewswire)
29.04.24	Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate (GlobeNewswire)
22.04.24	Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such (GlobeNewswire)
16.04.24	Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S (GlobeNewswire)
02.04.24	Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S. (GlobeNewswire)
21.03.24	Bavarian Nordic A/S – Notice Convening Annual General Meeting (GlobeNewswire)
13.03.24	Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland (GlobeNewswire)
12.03.24	Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such (GlobeNewswire)
06.03.24	Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

22.08.24		Bavarian Nordic-Aktie im Rally-Modus: Bavarian Nordic übertrifft Erwartungen um Längen
22.08.24		Ausblick: Bavarian Nordic legt Quartalsergebnis vor
20.08.24		Bavarian Nordic-Aktie dreht ins Minus: Produktion von Mpox-Impfstoff wird gesteigert - Halbjahreszahlen stehen an
23.08.22		Ausblick: Bavarian Nordic gewährt Anlegern Blick in die Bücher

22.08.24

Bavarian Nordic-Aktie im Rally-Modus: Bavarian Nordic übertrifft Erwartungen um Längen

22.08.24

Ausblick: Bavarian Nordic legt Quartalsergebnis vor

20.08.24

Bavarian Nordic-Aktie dreht ins Minus: Produktion von Mpox-Impfstoff wird gesteigert - Halbjahreszahlen stehen an

23.08.22

Ausblick: Bavarian Nordic gewährt Anlegern Blick in die Bücher

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Bavarian Nordic A/S

Aktien Top/Flop

Bavarian Nordic Peer Group Nachrichten

Meistgelesene Nachrichten